This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) provides $236,250 in funding to the University of California, Los Angeles (UCLA) to investigate the impacts of aerosolized tobacco and cannabis products on the interaction between Streptococcus mutans and Candida albicans, which are major contributors to dental caries.
The study aims to evaluate how exposure to nicotine...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $106,988 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to The Ohio State University. The 18-month grant, running from March 1, 2024 to August 31, 2024, will fund research to investigate the impact of e-cigarettes on oral wound healing. Using an integrated 'omics' approach, the project will quantify the clinical effects of e-cigarette use on oral wound healing in a longitudinal...
This $623,177 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to examine the effects of maternal exposure to electronic nicotine delivery system (ENDS) aerosols during pregnancy on addiction-related behaviors and neurobiology in offspring. The Hennepin Healthcare Research Institute (HHRI), a non-profit research organization, will conduct this study in animal models to assess the impacts...
The National Institute on Drug Abuse (NIDA) awarded a $1,973,823 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to the Medical University of South Carolina (MUSC) to evaluate a tobacco harm reduction strategy among clients enrolled in substance use disorder (SUD) treatment. The study will compare the efficacy of switching to electronic nicotine delivery systems (ENDS) versus using nicotine replacement therapy (NRT) to promote abstinence from cigarettes. The project...
This $720,855 federal Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program supports the "ENDS Aerosol Particle Deposition, In Utero Exposures and Children's Respiratory Health Effects (ENDURE)" consortium. The project aims to investigate the respiratory health impacts on children caused by in utero exposure to electronic nicotine delivery system (ENDS) aerosols, with a focus on electronic...
The National Institutes of Health (NIH), through the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077), awarded a $669,321 project grant to the Regents of the University of California at Riverside (UC Riverside). The grant supports a 1-year study to characterize new and emerging ingredients, acids, toxicants, and indicators of non-tobacco nicotine in electronic cigarette (e-cigarette) products. The research will involve:
Analyzing 600 commercial...
This $784,418 federal Project Grant awarded by the National Institutes of Health (CFDA 93.077 - Family Smoking Prevention and Tobacco Control Act Regulatory Research) to Yale University will develop and evaluate new labeling approaches to improve public understanding of nicotine levels in electronic nicotine delivery systems (ENDS).
The project aims to 1) refine a new nicotine concentration label that could replace current FDA-required labels, and 2) develop novel labels for communicating...
This $549,555.45 Project Grant award from the National Institutes of Health (NIH) Office of the Director supports research under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077). The award will fund a cross-sectional study to investigate the relationship between electronic cigarette (e-cigarette) use and exposure to chemical constituents of concern (CCOC), such as metals and aldehydes, as well as the association with respiratory health outcomes...
This $187,500.00 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, will fund research at North Carolina Central University (NCCU) to assess the impact of vaping on lung health and susceptibility to pulmonary infections.
The key objectives of this project are to: 1) model the effects of e-cigarette exposure on human bronchial epithelial cells, 2) evaluate the impact of vaping on immune cell...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) provides $611,084 to the University of Southern California (USC) to conduct research on the effects of nicotine concentration and pH levels in nicotine pouches on product appeal, sensory attributes, and abuse liability among young adult dual users of nicotine pouches and e-cigarettes.
The...
EARLY PERIODONTAL HEALTH IMPACTS OF ELECTRONIC NICOTINE DELIVERY SYSTEM (ENDS) USAGE - PROJECT SUMMARY THE USE OF ELECTRONIC NICOTINE DELIVERY SYSTEMS (ENDS) INCREASES THE RISK OF A NUMBER OF DISEASES INCLUDING THOSE OF THE ORAL CAVITY. SPECIFICALLY, OF CONCERN IS THE INDUCTION OF GINGIVAL INFLAMMATION AND INCREASED SUSCEPTIBILITY TO BACTERIAL INVASION, ULTIMATELY LEADING TO THE DEVELOPMENT OF PERIODONTAL DISEASE (PD). HOW AND WHY ENDS USE MAY POSE PD RISK IS UNCLEAR AS THERE IS A LACK OF COMPREHENSIVE DATA ON USAGE BEHAVIORS, EXPOSURES, AND DISEASE OUTCOMES. FURTHER, THERE IS A LACK OF EARLY INDICATORS OF PD ASSOCIATED WITH ENDS USAGE, WHICH IMPEDES INITIAL DIAGNOSIS AND THE DEVELOPMENT OF DISEASE PREVENTION STRATEGIES. WE HYPOTHESIZE EARLY INDICATORS OF ADVERSE ENDS-RELATED ORAL HEALTH OUTCOMES CAN BE IDENTIFIED AND EXPLAINED BY VARIATIONS IN ENDS PREFERENCE/USAGE AND BIOLOGICAL RESPONSES. TO ADDRESS THIS HYPOTHESIS, WE WILL ESTABLISH A BEHAVIOR-EXPOSURE- TOXICITY-DISEASE PARADIGM UTILIZING AIMS SPECIFICALLY DESIGNED TO EVALUATE ENDS USAGE AND CLINICAL MANIFESTATIONS OF ORAL DISEASE (AIM 1), COMMON ENDS PRODUCTS AND MOLECULAR MECHANISMS OF DISEASE (AIM 2), AND TRANSLATABLE INDICATORS OF DISEASE SUSCEPTIBILITY (AIM 3). THIS INNOVATIVE APPROACH WILL FACILITATE OUR KNOWLEDGE REGARDING THE MECHANISMS AND BIOMARKERS OF ENDS-MEDIATED ORAL HEALTH EFFECTS THAT CAN BE DIRECTLY APPLIED TO DISEASE PREVENTION STRATEGIES. IN AIM 1, WE WILL RECRUIT COHORTS OF NEVER-ESTABLISHED TOBACCO USERS AND CURRENT EXCLUSIVE ENDS USERS TO EVALUATE ENDS USAGE BEHAVIORS, ORAL HEALTH, AND RISK FACTORS. IN THIS AIM, WE WILL EMPLOY AN ESTABLISHED SOCIAL MEDIA RECRUITMENT STRATEGY TO RECRUIT PARTICIPANTS AND EVALUATE PARTICIPANT CHARACTERISTICS, ENDS USAGE, AND ORAL HEALTH HISTORY VIA FOCUSED QUESTIONNAIRES. ADDITIONALLY, ENDS USAGE WILL BE EXAMINED THROUGH REAL-TIME MONITORING OF ENDS PUFFING TOPOGRAPHY. CLINICAL MANIFESTATIONS OF DISEASE WILL BE ASSESSED BY AN ORAL HEALTH EXAM AND EXAMINATION OF THE SUBGINGIVAL MICROBIOME. TO ELUCIDATE THE ROLE OF PRODUCT-BASED ENDS EXPOSURES WE WILL UTILIZE AN IN VITRO AIR LIQUID INTERFACE MODEL SYSTEM TO EXPOSE PRIMARY GINGIVAL KERATINOCYTE/MACROPHAGE SPHEROIDS TO AEROSOLS IN AIM 2. THESE EXPOSURE SCENARIOS WILL UTILIZE ESTABLISHED PROTOCOLS FOR COMPARATIVE TOXICITY ASSESSMENTS WHILE ALSO INCORPORATING EXPOSURES REPRESENTATIVE OF ENDS USAGE FROM OUR RECRUITED PARTICIPANTS. SPECIFICALLY, THESE IN VITRO EXPERIMENTS WILL ASSESS BRAND-SPECIFIC MODULATION OF INFLAMMATION, OXIDATIVE STRESS, DNA DAMAGE/REPAIR, EPITHELIAL-MESENCHYMAL TRANSITIONS, AND BACTERIAL INVASION. IN AIM 3, WE WILL UTILIZE A MOLECULAR EPIDEMIOLOGY APPROACH TO ASSESS THE IMPACT OF ENDS USAGE BY THE EXAMINATION OF PARTICIPANT SALIVA, GINGIVAL CELLS, AND SUBGINGIVAL PLAQUES. THESE REPRESENT READILY AVAILABLE MATRICES TO EXAMINE EARLY INDICATORS OF ORAL DISEASE AND PD INITIATION INCLUDING BIOMARKERS OF INFLAMMATION, OXIDATIVE STRESS, DNA DAMAGE/REPAIR, EPITHELIAL-MESENCHYMAL TRANSITIONS, AND MICROBIAL ALTERATIONS. SPECIFICALLY, WE AIM TO ESTABLISH A PATHWAY BETWEEN PARTICIPANT CHARACTERISTICS, ENDS USAGE, AND TOXICOLOGICAL MECHANISMS CONTRIBUTING TO PD DEVELOPMENT THAT CAN BE APPLIED TO PROTECT PUBLIC HEALTH.